lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

The Efficacy and Safety of Bamlanivimab Treatment Against COVID-19:A Meta-Analysis

26 Pages Posted: 1 Sep 2021

See all articles by Huairong Xiang

Huairong Xiang

Central South University - Department of Pharmacy

Bei He

Central South University - Department of Pharmacy

Yun Li

Central South University - Department of Pharmacy

Xuan Cheng

Central South University - Department of Pharmacy

Qi-zhi Zhang

Central South University - Department of Pharmacy

Wen-xing Peng

Central South University - Department of Pharmacy

More...

Abstract

Background: Bamlanivimab is routinely used in the treatment of coronavirus disease 2019 (COVID-19) in worldwide. We performed a meta-analysis to investigate the efficacy and safety of bamlanivimab treatment in patients with COVID-19. 

Methods: We searched articles from Web of Science, PubMed, Embase, the Cochrane Library and MedRxiv between 30 January 2020 and August 5, 2021. We selected randomized clinical trials (RCTs) and observational studies with a control group to assess the efficiency of bamlanivimab in treating patients with COVID-19. 

Results: Our meta-analysis retrieved 3 RCTs and 7 cohort studies including 14461 patients. Bmlanivimab may help outpatients to prevent hospitalization or emergency department visit (RR 0.41 95%CI 0.29 to 0.58), reduce ICU admission (RR 0.47 95%CI 0.23 to 0.92) and mortality (RR 0.32 95%CI 0.13 to 0.77) from the disease. The combination of bamlanivimab and etesevimab may had a greater potential for positive treatment outcome. 

Conclusion: Bamlanivimab has demonstrated clinical efficacy on mild or moderate ill patients with COVID-19 to prevent hospitalization, reduce severity and mortality from the disease . Combinations of two or more monoclonal antibody increase the effect. Well-designed clinical trials to identify the clinical and biochemical characteristics in COVID-19 patients’ population that could benefit from bamlanivimab are warranted in the future.

Funding Statement: None to declare.

Declaration of Interests: The authors declared there are no competing interests.

Keywords: bamlanivimab; COVID-19; Immunotherapy

Suggested Citation

Xiang, Huairong and He, Bei and Li, Yun and Cheng, Xuan and Zhang, Qi-zhi and Peng, Wen-xing, The Efficacy and Safety of Bamlanivimab Treatment Against COVID-19:A Meta-Analysis. Available at SSRN: https://ssrn.com/abstract=3914653 or http://dx.doi.org/10.2139/ssrn.3914653

Huairong Xiang

Central South University - Department of Pharmacy

Hunan Sheng, 410008
China

Bei He

Central South University - Department of Pharmacy

Hunan Sheng, 410008
China

Yun Li

Central South University - Department of Pharmacy

Hunan Sheng, 410008
China

Xuan Cheng

Central South University - Department of Pharmacy

Hunan Sheng, 410008
China

Qi-zhi Zhang

Central South University - Department of Pharmacy

Hunan Sheng, 410008
China

Wen-xing Peng (Contact Author)

Central South University - Department of Pharmacy ( email )

Hunan Sheng, 410008
China

Click here to go to TheLancet.com

Paper statistics

Downloads
24
Abstract Views
283
PlumX Metrics